

Fenoflox 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats

Authorised

- Enrofloxacin

Product identification

Medicine name:

Fenoflox 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats
CHANENRO 50 MG/ML SOLUTION INJECTABLE POUR BOVINS, PORCINS, CHIENS ET CHATS

Active substance:

Enrofloxacin

Target species:

Pig
Cattle
Dog
Cat

Route of administration:

Intramuscular use
Intravenous use
Subcutaneous use

Product details

Active substance and strength:

Enrofloxacin

50.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Pig**

- Meat and offal. 13 day

Intravenous use:

- **Cattle**

- Meat and offal. 5 day

Subcutaneous use:

- **Cattle**

- Meat and offal. 12 day

- **Dog**

- **Cat**

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01MA90

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

France

Package description:

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

250 ml No. of containers in a carton: 20 x 250 ml

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

250 ml No. of containers in a carton: 15 x 250 ml

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

250 ml No. of containers in a carton: 12 x 250 ml

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

250 ml No. of containers in a carton: 10 x 250 ml

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

250 ml No. of containers in a carton: 5 x 250 ml

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

250 ml No. of containers in a carton: 1 x 250 ml

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

100 ml No. of containers in a carton: 20 x 100 ml

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

100 ml No. of containers in a carton: 15 x 100 ml

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

100 ml No. of containers in a carton: 12 x 100 ml

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

100 ml No. of containers in a carton: 10 x 100 ml

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

100 ml No. of containers in a carton: 5 x 100 ml

Container material: Type I Amber Glass Container closure: Grey teflonised chlorobutyl rubber stopper with an aluminium cap Container colour: Amber Container volume:

100 ml No. of containers in a carton: 1 x 100 ml

Additional information

Entitlement type:

Marketing Authorisation

Marketing authorisation holder:

Chanelle Pharmaceuticals Manufacturing Limited

Marketing authorisation date:

17/02/2010

Manufacturing sites for batch release:

Labiana Life Sciences S.A.

Chanelle Pharmaceuticals Manufacturing Limited

Responsible authority:

National Veterinary Medicines Agency

Authorisation number:

FR/V/7839791 4/2010

Date of authorisation status change:

22/12/2021

Reference member state:

Ireland

Procedure number:

IE/V/0223/001

Concerned member states:

Austria Belgium Cyprus Czechia Finland France Germany Hungary Italy
Luxembourg Poland Portugal Slovakia United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Source URL: <https://medicines.health.europa.eu/veterinary/600000051587>